BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update

Rhea-AI Summary

BrainStorm Cell Therapeutics (OTCQB: BCLI), a developer of adult stem cell therapeutics for neurodegenerative diseases, will host its Q2 2025 financial results conference call on August 14, 2025, at 8:30 AM ET.

The call will feature presentations from key executives including CEO Chaim Lebovits, COO Hartoun Hartounian, CMO Bob Dagher, and Interim CFO Alla Patlis, followed by a Q&A session. Investors can submit questions in advance to q@brainstorm-cell.com by August 12, 2025, at 10:00 AM ET.

Call Scheduled for August 14, 2025, at 8:30 AM Eastern Time

NEW YORK, Aug. 8, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call and webcast to update shareholders on financial results for the second quarter of 2025, at 8.30 a.m. Eastern Time on August 14, 2025.

BrainStorm's President and Chief Executive Officer, Chaim Lebovits, will provide the update. Hartoun Hartounian, PhD, Chief Operating Officer, Bob Dagher, MD, Chief Medical Officer, and Alla Patlis, Interim Chief Financial Officer, will also participate in the call.  Following the prepared remarks, there will be a Q&A session with the investment community.

Participants are encouraged to submit their questions in advance of the call by sending them to: q@brainstorm-cell.com. Questions should be submitted by 10:00 a.m. Eastern Time on August 12, 2025.           

The investment community may participate in the conference call by dialing the following numbers:

Investor dial in:
U.S. Toll Free:                          877-545-0320                                 
International:                            973-528-0002                         

Participant Access Code: 601260 
Webcast URL:                          https://shorturl.at/xrBQQ             

Those that wish to listen to the replay of the conference call can do so by dialing the numbers below. The replay will be available until August 28, 2026.

Teleconference Replay Number:             

Toll Free:                                         877-481-4010                   

International:                               919-882-2331          

Replay Passcode:                         52831           

About BrainStorm Cell Therapeutics Inc.              
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company's proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection.           

NurOwn® is BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a second Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the "Floor Effect" - a critical challenge in measuring clinical outcomes in advanced ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging area of regenerative medicine. To learn more, visit www.brainstorm-cell.com.

Notice Regarding Forward-Looking Statements 
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), Special Protocol Assessment (SPA), the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.

CONTACTS

Investors:
Michael Wood
Phone: +1 646-597-6983       
mwood@lifesciadvisors.com  

Media:
Uri Yablonka, Chief Business Officer
Phone: +1 917-284-2911       
uri@brainstorm-cell.com

Logo - https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/brainstorm-to-announce-second-quarter-financial-results-and-provide-a-corporate-update-302524833.html

SOURCE BrainStorm Cell Therapeutics Inc.

FAQ

When is BrainStorm Cell Therapeutics (BCLI) Q2 2025 earnings call?

BrainStorm's Q2 2025 earnings call is scheduled for August 14, 2025, at 8:30 AM Eastern Time.

How can investors participate in BCLI's Q2 2025 earnings call?

Investors can dial U.S. Toll Free: 877-545-0320 or International: 973-528-0002 with Participant Access Code: 601260, or access the webcast online.

Who will present at BrainStorm's Q2 2025 earnings call?

The call will feature CEO Chaim Lebovits, COO Hartoun Hartounian, CMO Bob Dagher, and Interim CFO Alla Patlis.

How can investors submit questions for BCLI's Q2 earnings call?

Investors can submit questions to q@brainstorm-cell.com by August 12, 2025, at 10:00 AM ET.

Until when will BCLI's Q2 2025 earnings call replay be available?

The replay will be available until August 28, 2026, accessible via U.S. Toll Free: 877-481-4010 or International: 919-882-2331 with replay passcode: 52831.